AzTrials
AzTrials

Acute Heart Failure (AHF)NCT07541768

Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment.

A study testing In-person VExUS Training Program and Remote VExUS Training Program in people with Acute Heart Failure (AHF) and Fluid Over-load, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
What is being tested?
In-person VExUS Training Program and Remote VExUS Training Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
1 siteSwitzerland
Study dates
20 Mar 2026to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Medical residents in general internal medicine
  • Basic ultrasound skills (POCUS component 1 or ≥200 scans)
  • Working at study site during study period

Who cannot join

  • SGUM certification in abdominal ultrasound
  • Advanced duplex ultrasound experience
  • Prior vascular/duplex training

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Caroline Rimensberger, MD contact

0041316322111

caroline.rimensberger@insel.ch

Claudio Schneider, MD contact

0041316322111

claudio.schneider@insel.ch

Switzerland1 site, 1 recruiting
  • Inselspital

    Bern, 3011

    General Internal Medicine, 0041316322367, sekretariat.meas@insel.ch

    Recruiting

Other trials in Switzerland

About this study

Official title: Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment: a Randomized Controlled Trial

This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and duplex sonography.

Read the detailed description

Accurate assessment of volume status is essential in managing acute heart failure but remains challenging in clinical practice. The VExUS score is a validated ultrasound-based tool integrating inferior vena cava diameter and Doppler assessment of hepatic, portal, and intrarenal veins.

This single-center randomized controlled trial compares two training modalities (in-person vs. remote) in medical residents with basic ultrasound skills. Participants will be randomized 1:1 to either training method and compared to a control group of expert physicians.

Primary outcomes include ultrasound image quality assessed using a standardized 100-point score. Secondary outcomes include time to acquisition, VExUS scoring accuracy, self-confidence, and acceptability of training methods.

Being tested
In-person VExUS Training Program, Remote VExUS Training Program, No intervention
Keywords
Vexus, Venous Excess Ultrasound, Point-of-Care Ultrasound, POCUS, Ultrasound Training, Medical Education, Volume Assessment, Venous Congestion, Duplex Ultrasound, Bedside Ultrasound
Medical subject headings
Hyperemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • In-person VExUS Training ProgramBehavioural

    In-person training consisting of a 1-hour theoretical introduction followed by a 3-hour supervised hands-on ultrasound training session focusing on acquisition and interpretation of the VExUS score.

  • Remote VExUS Training ProgramBehavioural

    Remote training consisting of an e-learning module followed by independently performed ultrasound examinations with asynchronous expert feedback (via phone or email).

  • No interventionOther

    SGUM-certified physicians performing VExUS examinations as expert reference standard.

Study groups in NCT07541768
Study groupRoleWhat they receive
In-person TrainingExperimental1-hour theoretical introduction 3-hour supervised practical ultrasound session Group-based hands-on training with expert coach
Receives: Behavioral: In-person VExUS Training Program
Remote TrainingExperimentalE-learning theoretical module 20 independently performed ultrasound exams Asynchronous expert feedback (phone/email)
Receives: Behavioral: Remote VExUS Training Program
Control (Expert Physicians)Active comparatorSGUM-certified physicians performing VExUS examinations
Receives: Other: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ultrasound Image Quality Score

    The primary outcome will be a quality score, adapted from a quality score used in a previous randomized controlled trial which investigated a simulator-based training program for transoesophageal echocardiography.11 The quality score will include items commonly used for assessment of ultrasound quality: angle and depth, overall clarity, visualization of the anatomical structures, focus, doppler gain, scale and baseline resulting in a maximum achievable quality score of 100 points. If multiple images of the predefined views are captured, each image will be rated, and the best rating will be kept to calculate the final score. If a view is missing, 0 point will be awarded for that view.

    All ultrasound images will be independently assessed by experts for abdominal sonography and use Doppler sonography in their daily clinical practice and are blinded to the role (resident vs. SGUM-certified physician) and training (in-person vs. remote) program of the participants.

    Measured: From training until 6 months after completion of training

Secondary outcomes (5)
  1. Time for Image Acquisition and Interpretation

    Time required by participants to perform the ultrasound examination and interpret the images during VExUS assessment

    Measured: From training until 6 months after completion of training

  2. Change in self-confidence in performing VExUS assessment

    Self-reported confidence measured using a Likert-scale questionnaire before and after training

    Measured: From baseline (before training) to immediately after completion of training

  3. Acceptability of the program (quantitative assessment)

    Acceptability of the program will be assessed using a structured survey with 5-point Likert scale items based on an implementation framework (e.g., Theoretical Domains Framework). Results will be reported as mean scores or median values on a 5-point scale, where higher scores indicate greater acceptability.

    Measured: Immediately after completion of training and during the outcome assessment period (within 2 months after training)

  4. VEXUS score

    The Venous Excess Ultrasound Score (VExUS) is a semi-quantitative ultrasound-based score used to assess systemic venous congestion by combining inferior vena cava (IVC) diameter and Doppler flow patterns of abdominal veins, including hepatic, portal, and intrarenal veins. The score ranges from 0 to 3, with 0 indicating no congestion, 1 indicating mild congestion, 2 indicating moderate congestion, and 3 indicating severe venous congestion. Higher scores indicate greater venous congestion and worse clinical status.

    Measured: From training until 6 months after completion of training

  5. Acceptability of the program (qualitative assessment)

    Acceptability, including perceived barriers and facilitators to implementation, will be explored through semi-structured interviews. Data will be analyzed using thematic analysis guided by an implementation framework.

    Measured: Immediately after completion of training and during the outcome assessment period (within 2 months after training)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2026
  2. Study start20 Mar 2026
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
23 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07541768
Sponsor's protocol ID
VEXUS Teaching
Status last verified
Apr 2026
First submitted
31 Mar 2026
Last updated
21 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing In-person VExUS Training Program and Remote VExUS Training Program in people with Acute Heart Failure (AHF) and Fluid Over-load, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Caroline Rimensberger, MD (0041316322111, caroline.rimensberger@insel.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ultrasound Image Quality Score (time frame: From training until 6 months after completion of training). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in